Intrinsic value of Catalent - CTLT

Previous Close

$38.22

  Intrinsic Value

$26.11

stock screener

  Rating & Target

sell

-32%

Previous close

$38.22

 
Intrinsic value

$26.11

 
Up/down potential

-32%

 
Rating

sell

We calculate the intrinsic value of CTLT stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 5.1

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  17.90
  16.61
  15.45
  14.40
  13.46
  12.62
  11.86
  11.17
  10.55
  10.00
  9.50
  9.05
  8.64
  8.28
  7.95
  7.66
  7.39
  7.15
  6.94
  6.74
  6.57
  6.41
  6.27
  6.14
  6.03
  5.93
  5.83
  5.75
  5.68
  5.61
Revenue, $m
  2,447
  2,853
  3,294
  3,769
  4,276
  4,816
  5,386
  5,988
  6,620
  7,282
  7,974
  8,695
  9,447
  10,229
  11,042
  11,887
  12,766
  13,679
  14,627
  15,614
  16,639
  17,706
  18,816
  19,972
  21,176
  22,431
  23,740
  25,105
  26,530
  28,017
Variable operating expenses, $m
  2,135
  2,467
  2,828
  3,216
  3,632
  4,073
  4,541
  5,033
  5,550
  6,092
  6,527
  7,117
  7,732
  8,372
  9,038
  9,730
  10,449
  11,196
  11,973
  12,780
  13,620
  14,493
  15,402
  16,348
  17,334
  18,361
  19,432
  20,549
  21,715
  22,933
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  2,135
  2,467
  2,828
  3,216
  3,632
  4,073
  4,541
  5,033
  5,550
  6,092
  6,527
  7,117
  7,732
  8,372
  9,038
  9,730
  10,449
  11,196
  11,973
  12,780
  13,620
  14,493
  15,402
  16,348
  17,334
  18,361
  19,432
  20,549
  21,715
  22,933
Operating income, $m
  312
  386
  466
  552
  644
  742
  846
  955
  1,070
  1,190
  1,447
  1,578
  1,714
  1,856
  2,004
  2,157
  2,317
  2,482
  2,654
  2,833
  3,019
  3,213
  3,415
  3,624
  3,843
  4,071
  4,308
  4,556
  4,814
  5,084
EBITDA, $m
  567
  661
  763
  873
  990
  1,115
  1,247
  1,387
  1,533
  1,686
  1,847
  2,014
  2,188
  2,369
  2,557
  2,753
  2,957
  3,168
  3,388
  3,616
  3,854
  4,101
  4,358
  4,626
  4,904
  5,195
  5,498
  5,814
  6,144
  6,489
Interest expense (income), $m
  81
  112
  139
  168
  199
  233
  269
  307
  348
  390
  435
  482
  532
  583
  636
  692
  750
  810
  872
  937
  1,004
  1,075
  1,147
  1,223
  1,302
  1,384
  1,470
  1,559
  1,652
  1,749
  1,850
Earnings before tax, $m
  200
  247
  298
  353
  412
  473
  539
  607
  679
  754
  965
  1,046
  1,131
  1,220
  1,312
  1,408
  1,507
  1,610
  1,717
  1,829
  1,945
  2,066
  2,191
  2,322
  2,459
  2,601
  2,749
  2,904
  3,065
  3,234
Tax expense, $m
  54
  67
  81
  95
  111
  128
  145
  164
  183
  204
  260
  283
  305
  329
  354
  380
  407
  435
  464
  494
  525
  558
  592
  627
  664
  702
  742
  784
  828
  873
Net income, $m
  146
  181
  218
  258
  300
  346
  393
  443
  496
  551
  704
  764
  826
  891
  958
  1,028
  1,100
  1,175
  1,254
  1,335
  1,420
  1,508
  1,600
  1,695
  1,795
  1,898
  2,007
  2,120
  2,238
  2,361

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  4,071
  4,748
  5,481
  6,271
  7,115
  8,013
  8,962
  9,964
  11,015
  12,116
  13,267
  14,468
  15,718
  17,019
  18,373
  19,779
  21,241
  22,760
  24,339
  25,980
  27,686
  29,461
  31,308
  33,232
  35,235
  37,324
  39,501
  41,772
  44,143
  46,618
Adjusted assets (=assets-cash), $m
  4,071
  4,748
  5,481
  6,271
  7,115
  8,013
  8,962
  9,964
  11,015
  12,116
  13,267
  14,468
  15,718
  17,019
  18,373
  19,779
  21,241
  22,760
  24,339
  25,980
  27,686
  29,461
  31,308
  33,232
  35,235
  37,324
  39,501
  41,772
  44,143
  46,618
Revenue / Adjusted assets
  0.601
  0.601
  0.601
  0.601
  0.601
  0.601
  0.601
  0.601
  0.601
  0.601
  0.601
  0.601
  0.601
  0.601
  0.601
  0.601
  0.601
  0.601
  0.601
  0.601
  0.601
  0.601
  0.601
  0.601
  0.601
  0.601
  0.601
  0.601
  0.601
  0.601
Average production assets, $m
  1,889
  2,203
  2,543
  2,909
  3,301
  3,718
  4,158
  4,623
  5,111
  5,622
  6,156
  6,713
  7,293
  7,896
  8,524
  9,177
  9,855
  10,560
  11,292
  12,054
  12,846
  13,669
  14,526
  15,419
  16,348
  17,317
  18,327
  19,381
  20,481
  21,629
Working capital, $m
  387
  451
  520
  595
  676
  761
  851
  946
  1,046
  1,151
  1,260
  1,374
  1,493
  1,616
  1,745
  1,878
  2,017
  2,161
  2,311
  2,467
  2,629
  2,798
  2,973
  3,156
  3,346
  3,544
  3,751
  3,967
  4,192
  4,427
Total debt, $m
  2,569
  3,104
  3,684
  4,309
  4,977
  5,687
  6,438
  7,230
  8,062
  8,933
  9,843
  10,793
  11,782
  12,811
  13,882
  14,994
  16,150
  17,352
  18,601
  19,899
  21,249
  22,653
  24,114
  25,635
  27,220
  28,872
  30,594
  32,391
  34,266
  36,224
Total liabilities, $m
  3,220
  3,755
  4,336
  4,960
  5,628
  6,338
  7,089
  7,881
  8,713
  9,584
  10,494
  11,444
  12,433
  13,462
  14,533
  15,645
  16,802
  18,003
  19,252
  20,550
  21,900
  23,304
  24,765
  26,286
  27,871
  29,523
  31,245
  33,042
  34,917
  36,875
Total equity, $m
  851
  992
  1,146
  1,311
  1,487
  1,675
  1,873
  2,082
  2,302
  2,532
  2,773
  3,024
  3,285
  3,557
  3,840
  4,134
  4,439
  4,757
  5,087
  5,430
  5,786
  6,157
  6,543
  6,945
  7,364
  7,801
  8,256
  8,730
  9,226
  9,743
Total liabilities and equity, $m
  4,071
  4,747
  5,482
  6,271
  7,115
  8,013
  8,962
  9,963
  11,015
  12,116
  13,267
  14,468
  15,718
  17,019
  18,373
  19,779
  21,241
  22,760
  24,339
  25,980
  27,686
  29,461
  31,308
  33,231
  35,235
  37,324
  39,501
  41,772
  44,143
  46,618
Debt-to-equity ratio
  3.020
  3.130
  3.220
  3.290
  3.350
  3.400
  3.440
  3.470
  3.500
  3.530
  3.550
  3.570
  3.590
  3.600
  3.620
  3.630
  3.640
  3.650
  3.660
  3.660
  3.670
  3.680
  3.690
  3.690
  3.700
  3.700
  3.710
  3.710
  3.710
  3.720
Adjusted equity ratio
  0.209
  0.209
  0.209
  0.209
  0.209
  0.209
  0.209
  0.209
  0.209
  0.209
  0.209
  0.209
  0.209
  0.209
  0.209
  0.209
  0.209
  0.209
  0.209
  0.209
  0.209
  0.209
  0.209
  0.209
  0.209
  0.209
  0.209
  0.209
  0.209
  0.209

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  146
  181
  218
  258
  300
  346
  393
  443
  496
  551
  704
  764
  826
  891
  958
  1,028
  1,100
  1,175
  1,254
  1,335
  1,420
  1,508
  1,600
  1,695
  1,795
  1,898
  2,007
  2,120
  2,238
  2,361
Depreciation, amort., depletion, $m
  254
  275
  297
  321
  346
  373
  402
  432
  464
  497
  400
  436
  474
  513
  554
  596
  640
  686
  733
  783
  834
  888
  943
  1,001
  1,062
  1,124
  1,190
  1,259
  1,330
  1,405
Funds from operations, $m
  400
  455
  515
  578
  647
  719
  795
  875
  959
  1,047
  1,104
  1,200
  1,299
  1,403
  1,511
  1,623
  1,740
  1,861
  1,987
  2,118
  2,254
  2,396
  2,543
  2,696
  2,856
  3,023
  3,197
  3,378
  3,568
  3,765
Change in working capital, $m
  59
  64
  70
  75
  80
  85
  90
  95
  100
  105
  109
  114
  119
  124
  128
  134
  139
  144
  150
  156
  162
  169
  175
  183
  190
  198
  207
  216
  225
  235
Cash from operations, $m
  342
  391
  445
  504
  566
  633
  705
  780
  860
  943
  995
  1,086
  1,181
  1,280
  1,383
  1,490
  1,601
  1,717
  1,837
  1,962
  2,092
  2,227
  2,368
  2,514
  2,666
  2,825
  2,990
  3,163
  3,342
  3,530
Maintenance CAPEX, $m
  -104
  -123
  -143
  -165
  -189
  -214
  -241
  -270
  -300
  -332
  -365
  -400
  -436
  -474
  -513
  -554
  -596
  -640
  -686
  -733
  -783
  -834
  -888
  -943
  -1,001
  -1,062
  -1,124
  -1,190
  -1,259
  -1,330
New CAPEX, $m
  -286
  -314
  -340
  -366
  -392
  -417
  -441
  -464
  -488
  -511
  -534
  -557
  -580
  -604
  -628
  -653
  -678
  -705
  -732
  -761
  -792
  -824
  -857
  -892
  -930
  -969
  -1,010
  -1,054
  -1,100
  -1,148
Cash from investing activities, $m
  -390
  -437
  -483
  -531
  -581
  -631
  -682
  -734
  -788
  -843
  -899
  -957
  -1,016
  -1,078
  -1,141
  -1,207
  -1,274
  -1,345
  -1,418
  -1,494
  -1,575
  -1,658
  -1,745
  -1,835
  -1,931
  -2,031
  -2,134
  -2,244
  -2,359
  -2,478
Free cash flow, $m
  -49
  -45
  -38
  -28
  -14
  3
  23
  46
  72
  100
  96
  129
  165
  202
  242
  284
  327
  372
  419
  467
  517
  569
  623
  678
  735
  794
  855
  919
  984
  1,052
Issuance/(repayment) of debt, $m
  490
  535
  580
  624
  668
  710
  751
  792
  832
  871
  910
  950
  989
  1,029
  1,070
  1,113
  1,156
  1,202
  1,249
  1,298
  1,350
  1,404
  1,461
  1,521
  1,585
  1,652
  1,722
  1,797
  1,875
  1,958
Issuance/(repurchase) of shares, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  490
  535
  580
  624
  668
  710
  751
  792
  832
  871
  910
  950
  989
  1,029
  1,070
  1,113
  1,156
  1,202
  1,249
  1,298
  1,350
  1,404
  1,461
  1,521
  1,585
  1,652
  1,722
  1,797
  1,875
  1,958
Total cash flow (excl. dividends), $m
  441
  490
  542
  597
  654
  713
  774
  838
  903
  971
  1,006
  1,079
  1,154
  1,232
  1,313
  1,396
  1,483
  1,574
  1,668
  1,765
  1,867
  1,973
  2,084
  2,199
  2,320
  2,446
  2,578
  2,715
  2,859
  3,010
Retained Cash Flow (-), $m
  -127
  -141
  -153
  -165
  -176
  -188
  -199
  -209
  -220
  -230
  -241
  -251
  -261
  -272
  -283
  -294
  -306
  -317
  -330
  -343
  -357
  -371
  -386
  -402
  -419
  -436
  -455
  -475
  -495
  -517
Prev. year cash balance distribution, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  314
  348
  389
  432
  477
  525
  575
  628
  683
  741
  765
  828
  892
  960
  1,030
  1,102
  1,178
  1,256
  1,338
  1,422
  1,511
  1,602
  1,698
  1,798
  1,901
  2,010
  2,123
  2,241
  2,364
  2,492
Discount rate, %
  9.20
  9.66
  10.14
  10.65
  11.18
  11.74
  12.33
  12.95
  13.59
  14.27
  14.99
  15.74
  16.52
  17.35
  18.22
  19.13
  20.08
  21.09
  22.14
  23.25
  24.41
  25.63
  26.91
  28.26
  29.67
  31.15
  32.71
  34.35
  36.07
  37.87
PV of cash for distribution, $m
  287
  290
  291
  288
  281
  270
  255
  237
  217
  195
  165
  143
  122
  102
  84
  67
  52
  40
  30
  22
  15
  11
  7
  5
  3
  2
  1
  1
  0
  0
Current shareholders' claim on cash, %
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0
  100.0

Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels. The Drug Delivery Solutions segment is engaged in the formulation, development and manufacturing of prescription and consumer and animal health products; blow-fill seal unit dose manufacturing; biologic cell line development; analytical and bioanalytical development, and testing services. The Clinical Supply Services segment is engaged in manufacturing, packaging, labeling, storage, distribution and inventory management for clinical trials of drugs and biologics for patient kits; FastChain clinical supply service; clinical e-solutions and informatics, and global comparator sourcing services.

FINANCIAL RATIOS  of  Catalent (CTLT)

Valuation Ratios
P/E Ratio 43.4
Price to Sales 2.3
Price to Book 6.6
Price to Tangible Book
Price to Cash Flow 15.9
Price to Free Cash Flow 29.9
Growth Rates
Sales Growth Rate 12.3%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 0%
Cap. Spend. - 3 Yr. Gr. Rate 2.8%
Financial Strength
Quick Ratio 12
Current Ratio 0.1
LT Debt to Equity 283.8%
Total Debt to Equity 287.3%
Interest Coverage 3
Management Effectiveness
Return On Assets 5.4%
Ret/ On Assets - 3 Yr. Avg. 8.1%
Return On Total Capital 4.2%
Ret/ On T. Cap. - 3 Yr. Avg. 5.8%
Return On Equity 16.2%
Return On Equity - 3 Yr. Avg. 65%
Asset Turnover 0.6
Profitability Ratios
Gross Margin 31.6%
Gross Margin - 3 Yr. Avg. 32.3%
EBITDA Margin 17.5%
EBITDA Margin - 3 Yr. Avg. 19.1%
Operating Margin 11%
Oper. Margin - 3 Yr. Avg. 11.6%
Pre-Tax Margin 6.6%
Pre-Tax Margin - 3 Yr. Avg. 6.9%
Net Profit Margin 5.3%
Net Profit Margin - 3 Yr. Avg. 7.6%
Effective Tax Rate 19.1%
Eff/ Tax Rate - 3 Yr. Avg. -14.4%
Payout Ratio 0%

CTLT stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the CTLT stock intrinsic value calculation we used $2075.4 million for the last fiscal year's total revenue generated by Catalent. The default revenue input number comes from 0001 income statement of Catalent. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our CTLT stock valuation model: a) initial revenue growth rate of 17.9% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 9.2%, whose default value for CTLT is calculated based on our internal credit rating of Catalent, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Catalent.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of CTLT stock the variable cost ratio is equal to 88.2%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for CTLT stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Catalent.

Corporate tax rate of 27% is the nominal tax rate for Catalent. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the CTLT stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for CTLT are equal to 77.2%.

Life of production assets of 15.4 years is the average useful life of capital assets used in Catalent operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for CTLT is equal to 15.8%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $723.5 million for Catalent - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 133.369 million for Catalent is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Catalent at the current share price and the inputted number of shares is $5.1 billion.

RELATED COMPANIES Price Int.Val. Rating
REPH Recro Pharma 6.84 0.16  str.sell
PFE Pfizer 43.52 34.10  hold
ZGNX Zogenix 39.97 3.64  str.sell
JNJ Johnson&Johnso 144.68 176.79  buy
GSK GlaxoSmithKlin 41.40 350.10  str.buy
IBIO iBio 0.780 4.72  str.buy

COMPANY NEWS

▶ What Does Catalent Incs (NYSE:CTLT) P/E Ratio Tell You?   [Nov-07-18 07:21AM  Simply Wall St.]
▶ Catalent: Fiscal 1Q Earnings Snapshot   [07:48AM  Associated Press]
▶ New Strong Sell Stocks for September 19th   [Sep-19-18 07:12AM  Zacks]
▶ Catalent (CTLT) Q4 Earnings Top Estimates   [Aug-28-18 08:50AM  Zacks]
▶ Catalent: Fiscal 4Q Earnings Snapshot   [07:51AM  Associated Press]
▶ Catalent (CTLT) Catches Eye: Stock Jumps 5.2%   [Jul-26-18 08:42AM  Zacks]
▶ Catalent, Inc. Announces Public Offering of Common Stock   [Jul-23-18 04:05PM  Business Wire]
▶ WeissLaw LLP Investigates Juniper Pharmaceuticals, Inc.   [Jul-05-18 04:33PM  PR Newswire]
▶ Company News For Jul 5, 2018   [09:40AM  Zacks]
▶ Catalent to acquire Boston's Juniper Pharmaceuticals for $128M   [Jul-03-18 11:07AM  American City Business Journals]
▶ Tenant on former Marion Labs campus completes $5.5M expansion   [May-22-18 03:39PM  American City Business Journals]
▶ Catalent: Fiscal 3Q Earnings Snapshot   [May-01-18 09:05AM  Associated Press]
▶ Catalent Q3 Earnings Outlook   [Apr-30-18 02:48PM  Benzinga]
▶ 5 Drug Stocks Poised to Surpass on Earnings This Quarter   [Apr-17-18 04:00PM  InvestorPlace]
▶ Edited Transcript of CTLT presentation 7-Mar-17 12:30pm GMT   [Apr-10-18 11:16AM  Thomson Reuters StreetEvents]
▶ Catalent Announces Changes to its Board of Directors   [Feb-20-18 07:45AM  Business Wire]
▶ [$$] Allergan Names Matthew Walsh New Finance Chief   [09:17AM  The Wall Street Journal]
▶ Catalent reports 2Q loss   [08:04AM  Associated Press]
▶ 5 Opioid Treatment Stocks   [06:52AM  Insider Monkey]
▶ New Strong Sell Stocks for January 3rd   [Jan-03-18 05:01AM  Zacks]
▶ New Strong Sell Stocks for December 29th   [Dec-29-17 09:17AM  Zacks]
▶ ETFs with exposure to Catalent, Inc. : December 27, 2017   [Dec-27-17 11:07AM  Capital Cube]
▶ Stocks Showing Rising Market Leadership: Catalent Earns 83 RS Rating   [Dec-07-17 03:00AM  Investor's Business Daily]
▶ ETFs with exposure to Catalent, Inc. : November 8, 2017   [Nov-08-17 05:51PM  Capital Cube]
▶ Catalent beats Street 1Q forecasts   [Nov-06-17 07:43AM  Associated Press]
▶ Catalent Completes Acquisition of Cook Pharmica   [Oct-24-17 02:00AM  Business Wire]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.